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Peter A. McCullough, MD, MPH,yz Ankit Mehta, MD,y Harold Szerlip, MDyC ardiac surgery in children has markedlyadvanced and is a mainstay for the treat-ment of serious congenital cardiac malfor-
mations. Because the heart, great vessels, and total
blood volume are much smaller in children than
in adults, the cardiopulmonary bypass procedure
is challenging with respect to maintaining organ
perfusion during cardiac surgery. Most pediatric
surgeries involves cross-clamping major vessels,
greater degrees of vascular repair, and operations
that, overall, are more complicated than common
coronary artery bypass graft surgeries in adults.
Another major difference between cardiac surgeries
in children and those in adults is that children un-
dergoing cardiac surgery are largely free of diabetes
and hypertension and, thus, have normal renal func-
tion and a full complement of functioning nephrons
capable of dramatically up-regulating response and
repair proteins after injury. Thus, children undergo-
ing cardiac surgery and cardiopulmonary bypass
are ideal for the study of ischemia and reperfusion
injury (cardiac surgery-associated acute kidney in-
jury [CSA-AKI]) to the normal human kidney (1).SEE PAGE 2753In this issue of the Journal, Basu et al. (2) report
the proteomic signals that are measurable in urine
from 345 children who underwent cardiac surgery.*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.Of note, children who developed AKI had much
longer (42% greater) periods of cardiopulmonary
bypass (135 vs. 95 min) than those who did not.
Using a different but established serum marker of
renal ﬁltration, cystatin-C, and a urinary biomarker,
neutrophil gelatinase-associated lipocalin (NGAL),
which is both constitutively and inducibly produced
in the distal nephron, the investigators were better
able to detect AKI (3). NGAL is a siderophore that
works to mop up unbound iron, which is released in
low levels during autophagy and normal cellular
housekeeping and in much larger quantities in the
setting of AKI. Thus, the release of unbound cata-
lytic iron due to hemolysis in cardiopulmonary
bypass and from renal tubular cells in AKI results in
rapid up-regulation of NGAL, which can be easily
measured in the urine (4). As shown in Figure 1,
Basu et al. (2) demonstrated that AKI, deﬁned by the
Kidney Disease Global Outcomes Initiative (KDIGO)
as a more severe and sustained rise in serum creati-
nine and reduction in urine output, is more readily
anticipated by use of a composite of plasma cystatin-
C (to indicate changes in renal ﬁltration) and urine
NGAL (to indicate renal tubular epithelial cell
response to injury) (5).
Because transient changes in serum creatinine
and urine output are common in children after
coming off cardiopulmonary bypass, there is a great
need for increased speciﬁcity for AKI in order to
anticipate the postoperative course. If this new
approach indicates AKI before elevation of serum
creatinine, instead of the usual postoperative care
pathway, avoidance of nephrotoxins, alerts for
renal drug dosing, close hemodynamic moni-
toring, and nephrology consultation would all come
into play. Although plasma and urine NGAL are
commercially available in Europe, and another urine
FIGURE 1 Conceptual Model of CSA-AKI
Conceptual models of CSA-AKI based on approved, commercially available renal ﬁltration
markers in plasma (sCr and/or CyC) and on markers produced by renal tubular epithelial
cells and measurable in urine. AKI ¼ acute kidney injury; Cr ¼ creatinine; CSA-AKI ¼ cardiac
surgery-associated acute kidney injury; CyC ¼ cystatin-C; GFR ¼ glomerular ﬁltration rate;
GST ¼ alpha-glutathione S-transferase; IGFBP-7 ¼ insulin-like growth factor-binding
protein 7; KIM-1 ¼ kidney injury molecule-1; L-FABP ¼ L-type fatty acid-binding
protein; NGAL ¼ neutrophil gelatinase-associated lipocalin; RRT ¼ renal replacement
therapy; sCr ¼ serum creatinine; TIMP2 ¼ tissue inhibitor of metalloproteinases-2.
McCullough et al. J A C C V O L . 6 4 , N O . 2 5 , 2 0 1 4
Improving AKI Detection D E C E M B E R 3 0 , 2 0 1 4 : 2 7 6 3 – 4
2764AKI marker, L-type fatty acid-binding protein,
is available in Japan, we await the commercial
availability of the ﬁrst U.S. Food and Drug
Administration-approved urine AKI assay (cell cycle
arrest proteins, insulin growth factor-binding
protein-7x tissue inhibitor of metalloproteinase-2)
(6). Deployment of this novel detection approach
for CSA-AKI in children and probably also in adults
holds great promise, not only for changes in clinical
care but for development of improved forms
of cardiopulmonary bypass, which may include
therapeutic aspects of ultraﬁltration or modiﬁcation
of plasma (free iron removal, cytokine modula-
tion, and others) (7). Although we believe that
cardiopulmonary bypass for children undergoing
cardiac surgery will continue to be used in most
cases, the implementation of novel biomarkers
represents a clear improvement on the decades-old
approach of serum creatinine monitoring and
hopefully will be an important developmental step
toward the future prevention and treatment of
CSA-AKI.
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